Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients.
Fossard G, Blond E, Balsat M, Morisset S, Giraudier S, Escoffre-Barbe M, Labussière-Wallet H, Heiblig M, Bert A, Etienne M, Drai J, Sobh M, Redonnet-Vernhet I, Lega JC, Mahon FX, Etienne G, Nicolini FE. Fossard G, et al. Among authors: sobh m. Haematologica. 2016 Mar;101(3):e86-90. doi: 10.3324/haematol.2015.135103. Epub 2015 Dec 3. Haematologica. 2016. PMID: 26635034 Free PMC article. No abstract available.
High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma.
El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, Faucher C, Sobh M, Revesz D, Hardan I, Fürst S, Blaise D, Mohty M. El-Cheikh J, et al. Among authors: sobh m. Haematologica. 2008 Mar;93(3):455-8. doi: 10.3324/haematol.12184. Epub 2008 Feb 20. Haematologica. 2008. PMID: 18287132 Free article.
Phase II prospective study of treosulfan-based reduced-intensity conditioning in allogeneic HSCT for hematological malignancies from 10/10 HLA-identical unrelated donor.
Michallet M, Sobh M, Milpied N, Bay JO, Fürst S, Harousseau JL, Mohty M, Nicolini FE, Labussière H, Tedone N, Morisset S, Vigouroux S, Baumgart J, Tabrizi R, Blaise D. Michallet M, et al. Among authors: sobh m. Ann Hematol. 2012 Aug;91(8):1289-97. doi: 10.1007/s00277-012-1429-y. Epub 2012 Feb 25. Ann Hematol. 2012. PMID: 22362122 Clinical Trial.
Impact of anti-HLA antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reduced-intensity conditioning regimens.
Detrait M, Dubois V, Sobh M, Morisset S, Tedone N, Labussière H, Gillis L, Barraco F, Cannas G, Ducastelle S, Fatoum J, Thomas X, Chelgoum Y, Nicolini FE, Michallet M. Detrait M, et al. Among authors: sobh m. Exp Hematol. 2012 Oct;40(10):792-9. doi: 10.1016/j.exphem.2012.06.003. Epub 2012 Jun 12. Exp Hematol. 2012. PMID: 22705505 Free article. Clinical Trial.
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.
Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I. Michallet M, et al. Among authors: sobh m. Cancer. 2013 Jan 1;119(1):107-14. doi: 10.1002/cncr.27686. Epub 2012 Jun 28. Cancer. 2013. PMID: 22744794 Free article.
Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Michallet M, Socié G, Mohty M, Sobh M, Bay JO, Morisset S, Labussière-Wallet H, Tabrizi R, Milpied N, Bordigoni P, El-Cheikh J, Blaise D. Michallet M, et al. Among authors: sobh m. Exp Hematol. 2013 Feb;41(2):127-33. doi: 10.1016/j.exphem.2012.10.008. Epub 2012 Oct 23. Exp Hematol. 2013. PMID: 23089183 Free article. Clinical Trial.
Double umbilical cord blood transplantation for hematological malignancies: a long-term analysis from the SFGM-TC registry.
Wallet HL, Sobh M, Morisset S, Robin M, Fegueux N, Fürst S, Mohty M, Deconinck E, Fouillard L, Bordigoni P, Rio B, Sirvent A, Renaud M, Dhedin N, Tabrizi R, Maury S, Buzyn A, Michel G, Maillard N, Cahn JY, Bay JO, Yakoub-Agha I, Huynh A, Schmidt-Tanguy A, Lamy T, Lioure B, Raus N, Marry E, Garnier F, Balère ML, Gluckman E, Rocha V, Socié G, Blaise D, Milpied N, Michallet M. Wallet HL, et al. Among authors: sobh m. Exp Hematol. 2013 Nov;41(11):924-33. doi: 10.1016/j.exphem.2013.05.297. Epub 2013 Jul 2. Exp Hematol. 2013. PMID: 23831606 Free article.
Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
Michallet M, Sobh M, El-Cheikh J, Morisset S, Sirvent A, Reman O, Cornillon J, Tabrizi R, Milpied N, Harousseau JL, Labussière H, Nicolini FE, Attal M, Moreau P, Mohty M, Blaise D, Avet-Loiseau H. Michallet M, et al. Among authors: sobh m. Exp Hematol. 2013 Dec;41(12):1008-15. doi: 10.1016/j.exphem.2013.08.003. Epub 2013 Aug 29. Exp Hematol. 2013. PMID: 23994781 Free article. Clinical Trial.
First application of the EBMT risk score in double umbilical cord blood transplantation for hematologic malignancies: significant impact on different outcomes.
Wallet HL, Sobh M, Robin M, Fegueux N, Fürst S, Mohty M, Yakoub-Agha I, Marry E, Rocha V, Blaise D, Milpied N, Nicolini FE, Michallet M. Wallet HL, et al. Among authors: sobh m. Exp Hematol. 2014 Mar;42(3):161-2. doi: 10.1016/j.exphem.2013.11.007. Epub 2013 Nov 20. Exp Hematol. 2014. PMID: 24269845 Free article. No abstract available.
280 results